The last time the FDA approved a new active sunscreen ingredient in the United States, the iPhone did not exist. Bill Clinton was halfway through his second term. The year was 1999. Since then: 26 years. Zero new UV filters added to the U.S. monograph. Meanwhile, Europe has approved nine more, Australia has approved several, Korea and Japan have approved more, and a quietly engineered molecule called bemotrizinol has been the gold-standard organic UV filter outside the U.S. for the better part of two decades.
That ends — possibly — this year. On December 11, 2025, the FDA issued proposed administrative order OTC000039 to amend OTC Monograph M020 and add bemotrizinol as a generally recognized as safe and effective (GRASE) active ingredient at concentrations up to 6%. The public comment period closed January 26, 2026. A GRASE determination is expected as early as March 2026 — slipped, but live. If finalized, bemotrizinol will be the first new Category 1 UV filter on the U.S. market in over a generation.
The interesting story is not that approval is finally happening. It is what the 26-year drought cost — and why bemotrizinol is genuinely better than what most Americans have been putting on their skin since the late 1990s.
The U.S. sunscreen shortfall, by the numbers
Europe approves 29 UV filters for use in sunscreen. The United States allows 16. On the UVA side specifically — the longer-wavelength radiation that drives photoaging, mitochondrial damage, and a significant fraction of melanoma risk — Europe has nine approved filters. The U.S. has four.
Of those four U.S. UVA filters, only one (avobenzone) provides meaningful protection across the full UVA range, and it is notoriously photo-unstable. Avobenzone degrades under sunlight unless it is paired with a photostabilizer — most commonly octocrylene, which has its own systemic-absorption issues. The American formulator is essentially building a UVA defense out of one fragile molecule and a chaperone. The European formulator gets to pick from a portfolio of stable, broad-spectrum options including bemotrizinol, bisoctrizole, ecamsule (Mexoryl SX), drometrizole trisiloxane (Mexoryl XL), and Tinosorb M.
This is why "European sunscreen feels better" is not a matter of taste. It is a regulatory artifact. The available chemistry produces lighter textures, better photostability, broader UVA protection per percent of active, and less reliance on the brute-force approach of high-concentration legacy filters like oxybenzone and homosalate — both of which Americans absorb into bloodstream at concentrations the FDA itself has flagged for further safety review.
What bemotrizinol actually is
Bemotrizinol — sold globally under the trade name Tinosorb S — is a large, hydrophobic, triazine-class organic UV filter engineered by Ciba (now part of BASF) in the late 1990s. Its INCI name is bis-ethylhexyloxyphenol methoxyphenyl triazine. It was designed from scratch to fix the structural weaknesses of the older organic filters: small molecules that easily penetrate skin, narrow absorption peaks, and rapid photodegradation.
Three properties define why it matters:
True broad-spectrum absorption. Bemotrizinol absorbs across the full UVB range (280–320 nm) and across both UVA II (320–340 nm) and UVA I (340–400 nm). Most legacy U.S. organic filters have a sharp absorption peak in one region and steep falloff outside it. Bemotrizinol has two broad absorption maxima, around 310 nm and 340 nm, producing a wide protective curve rather than a narrow spike. One molecule covers a range that previously required combining several.
Exceptional photostability. Bemotrizinol does not meaningfully degrade under sunlight. More importantly, it photostabilizes other filters around it — most notably avobenzone. The standard European formulation strategy uses small amounts of bemotrizinol specifically as a photostabilizer for avobenzone, allowing the avobenzone to keep working after several hours of sun exposure instead of collapsing within 30–60 minutes. Octocrylene does similar work in the U.S. — but with significantly more systemic absorption and emerging concerns about benzophenone contamination from octocrylene degradation. Bemotrizinol gives formulators a cleaner option.
Minimal skin penetration. The molecule is large (molecular weight 627 g/mol) and highly lipophilic. It partitions into the oil phase of an emulsion, sits on the upper stratum corneum, and largely stays there. The FDA's maximal usage trial (MUsT) data — submitted by DSM-Firmenich as part of the October 2024 OMOR application — showed steady-state plasma concentrations below the FDA's 0.5 ng/mL threshold for triggering additional carcinogenicity studies. This is significant because the same threshold is breached by avobenzone, oxybenzone, octocrylene, and ecamsule under normal use conditions. Most of what is in your current chemical sunscreen is getting into your blood. Bemotrizinol largely is not.
The 0.5 ng/mL line — and why it matters
The FDA's MUsT protocol is the most consequential piece of sunscreen regulation most consumers have never heard of. Under FDA's 2019 framework, if a sunscreen active demonstrates a steady-state plasma concentration above 0.5 ng/mL under maximal-usage conditions, the FDA effectively requires the manufacturer to provide systemic safety data equivalent to that of an oral pharmaceutical: 2-year rodent carcinogenicity studies, developmental and reproductive toxicology, the full pharmaceutical-grade workup.
This is a high bar. A 2019 FDA pilot study reported that under normal use of four common sunscreen ingredients — avobenzone, oxybenzone, octocrylene, and ecamsule — plasma concentrations exceeded the 0.5 ng/mL threshold after a single day of use, often by orders of magnitude. The agency requested additional safety data on most of the older organic filters, and that data has been slow to come.
Bemotrizinol passed the MUsT cleanly. The clinical pharmacology review specifically noted that the threshold for requiring additional carcinogenicity work was not breached, and the supporting toxicology package — including fertility and pre-/postnatal development studies — produced no safety signals. That, combined with two decades of European real-world use covering hundreds of millions of consumer applications and no signal of harm, is what made the FDA finally comfortable enough to issue OTC000039.
Why the gap was never about science
Bemotrizinol's safety data has been mature since the early 2000s. The European Scientific Committee on Cosmetic Products (SCCS) reviewed it in 1999 and found no evidence of toxicity or significant allergenicity. The Environmental Working Group rates it 1 on a 1–10 hazard scale, the cleanest rating they assign. It is approved at concentrations up to 10% in the EU, MERCOSUR, Australia, Korea, China, and ASEAN. Canada permits it up to 6%. The molecule has been studied across multiple regulatory regimes and has not produced the kinds of signals that hold up regulatory approval.
What held it up in the United States was the regulatory pathway itself. Until 2014, the FDA reviewed sunscreen ingredients under a system called Time and Extent Application (TEA), which had effectively stalled — by 2014, eight pending sunscreen filters had been waiting for FDA action for as long as 12 years. The Sunscreen Innovation Act of 2014 was supposed to fix this by imposing deadlines and adding the GRASE process for novel actives. It largely did not. The deadlines were missed. The data requirements were tightened, not loosened. The FDA in 2015 issued non-GRASE proposed orders on the entire backlog of pending filters, citing insufficient data — without specifying exactly what additional data would suffice.
The Modernization of Cosmetics Regulation Act (MoCRA) of 2022 finally provided the framework that could move bemotrizinol forward — the OTC Monograph Order Request (OMOR) process. DSM-Firmenich, which owns the global commercial rights to the molecule, submitted its OMOR in October 2024 with the MUsT data the FDA had been signaling it would accept. Fourteen months later, in December 2025, the FDA proposed approval.
The takeaway: every American sunburn and every avoidable bit of photoaging that happened between roughly 2005 and 2026 in the U.S. did not happen because the safer, better molecule did not exist. It happened because the agency-of-record could not get out of its own way for two decades.
What this changes — and what it does not
Assuming a final GRASE order lands in 2026, expect formulation reshuffling rather than a sudden mass switch. The 6% cap in the U.S. proposal is lower than the 10% allowed in most other jurisdictions, which limits how aggressively domestic formulators can use bemotrizinol as a primary UVA workhorse. The smart move — and the one experienced European formulators have been making for years — is to use bemotrizinol at moderate concentration (2–4%) specifically to photostabilize avobenzone at 2–3%, producing a sunscreen that maintains its UVA protection across a full day of wear without the photostability collapse that plagues current U.S. chemical sunscreens.
Expect the early movers to be the boutique chemical-sunscreen brands that have been quietly importing European formulas or pushing dermatologist-developed lines — the Supergoops, the EltaMDs, the Skinceuticals, and the newer players like Vacation and Naked Sundays. The mass-market brands (Banana Boat, Coppertone, Neutrogena's chemical line) will follow, but slowly — they have older formulations to recoup investment on and large supply chains that don't pivot quickly.
For mineral-sunscreen users (zinc oxide, titanium dioxide), bemotrizinol changes very little. Mineral sunscreens were already the answer for people who wanted broad-spectrum UVA protection without systemic absorption concerns. Bemotrizinol is the parallel answer for people who want chemical-sunscreen elegance — lighter texture, no white cast, easier daily wear — without giving up UVA protection or accepting high plasma levels of older filters. The two categories now stop being a forced choice.
What to do in the meantime
The final order has not been issued. Bemotrizinol is not yet legal in U.S.-sold sunscreens. For the next several months, the practical options remain the same:
The cleanest U.S.-legal path for broad-spectrum UVA protection without absorption concerns is still mineral — zinc oxide at 15–22%, ideally as the only active or paired with titanium dioxide. Modern formulations have largely solved the white cast problem, particularly tinted versions that use iron oxides to filter visible light as well. If you want chemical-sunscreen elegance now and are willing to accept current U.S. filters, prioritize formulas built around avobenzone with octocrylene as the photostabilizer and confirm "broad-spectrum" labeling.
For travelers, the older workaround still applies: a French pharmacy or a trip through Heathrow remains the easiest way to pick up European formulations using bemotrizinol, bisoctrizole, and the Mexoryl filters. La Roche-Posay Anthelios UVMune 400, Bioderma Photoderm, Avène Cleanance Sunscreen, and Vichy Capital Soleil all use bemotrizinol in their EU-market versions. None of those exact formulations are legally sold in the U.S., but they are not regulated for personal-use importation, and they remain the gold standard for what bemotrizinol-containing sunscreen actually looks and feels like on skin.
The bigger pattern
The bemotrizinol story is not really about one molecule. It is about a regulatory system that classified sunscreen actives as over-the-counter drugs in 1972 and then failed to update the pathway for the next half-century, leaving Americans with measurably worse sun protection than the rest of the developed world. The Sunscreen Innovation Act, MoCRA, and the OMOR process are the slow, partial corrections of that drift. Bemotrizinol is the first ingredient to actually make it through. Bisoctrizole, drometrizole trisiloxane, and several others remain in the queue.
If the GRASE order lands as expected, the next decade of U.S. sunscreen will look meaningfully different from the last two. Photoaging that was avoidable will become more avoidable. UVA protection that was thin will become thicker. And consumers will, for the first time in a generation, get to choose from a chemistry set that resembles what the rest of the world has been using since before TikTok existed.
The single best predictor of how your skin will look at 60 is how much UVA you absorb between now and then. The U.S. has been losing that race against the regulatory clock since the Clinton administration. The molecule that ends it is finally arriving — and you should be paying attention to which brands are first.